Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Top Page
Gossamer Bio
(NASDAQ:GOSS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.33
▼(-17.25% Downside)
Action:UpgradedDate:04/10/26
Overall score is low primarily due to very weak financial performance (widening losses, sharply higher cash burn, and negative equity). Technicals also remain bearish with the stock trading well below major moving averages, while recent corporate events add meaningful downside risk (Nasdaq bid-price deficiency and mixed Phase 3 outcome).
Positive Factors
Phase 3 subgroup efficacy signals
Prespecified subgroup and secondary endpoint benefits indicate seralutinib may have clinically meaningful efficacy in harder‑to‑treat PAH segments. This supports a targeted regulatory and commercial strategy that can be less costly and faster to pursue than a broad population approval, preserving upside in niche markets.
Negative Factors
Severe cash burn and negative free cash flow
A large, step‑up in cash burn materially shortens runway and forces near‑term financing decisions. Persistent negative FCF increases dilution or debt needs, may compel program prioritization or pauses, and elevates execution risk for multi‑year clinical plans absent new funding or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 subgroup efficacy signals
Prespecified subgroup and secondary endpoint benefits indicate seralutinib may have clinically meaningful efficacy in harder‑to‑treat PAH segments. This supports a targeted regulatory and commercial strategy that can be less costly and faster to pursue than a broad population approval, preserving upside in niche markets.
Read all positive factors
Gossamer Bio (GOSS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$94.02M
Dividend YieldN/A
Average Volume (3M)12.08M
Price to Earnings (P/E)―
Beta (1Y)1.41
Revenue Growth-58.17%
EPS Growth-116.24%
CountryUS
Employees144
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.21
Shares Outstanding234,696,270
10 Day Avg. Volume7,621,239
30 Day Avg. Volume12,077,612
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap2.82
Enterprise Value/Revenue5.48
Enterprise Value/Gross Profit5.50
Enterprise Value/Ebitda-1.66
Forecast
1Y Price Target
$4.40Price Target Upside1000.00% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-0.47
Revenue Forecast (FY)$25.78M
Gossamer Bio Business Overview & Revenue Model
Company Description
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is dev...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Gossamer Bio has historically not had recurring revenue from marketed products; instead, it has funded operations primarily through external financing and, where applicable, collaboration-related paym...
Gossamer Bio Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in Gossamer Bio's clinical trials, particularly with the completion of enrollment for the PROSERA study and strategic partnerships. However, there are challenges with delayed timelines and stringent enrollment criteria resulting in a high screening failure rate, alongside financial losses.Positive Updates
Successful Enrollment in PROSERA Study
Gossamer Bio announced the completion of patient enrollment for the Phase III PROSERA study focused on Seralutinib for PAH, with a total of 343 patients enrolled.
Negative Updates
Delayed Data Readout for PROSERA Study
The announcement of top-line results for the PROSERA study has been pushed to February 2026 due to extended enrollment and data cleaning processes.
Read all updates
Q1-2025 Updates
Positive
Negative
Successful Enrollment in PROSERA Study
Gossamer Bio announced the completion of patient enrollment for the Phase III PROSERA study focused on Seralutinib for PAH, with a total of 343 patients enrolled.
Read all positive updates
Company Guidance
During the Gossamer Bio Q1 2025 earnings call, the company provided a detailed update on their investigational treatment Seralutinib, particularly focusing on the Phase III PROSERA study for pulmonary arterial hypertension (PAH). The call highlighted the completion of patient screenings, with 343 patients enrolled and targeted to complete enrollment by mid-June. The study is powered to detect a 30-meter improvement in the six-minute walk distance at 24 weeks, with anticipated top-line results in February 2026. The baseline characteristics of enrolled patients, including an average six-minute walk distance of 376 meters and a mean NT-proBNP level of 96 ng/L, indicate a sicker population compared to prior studies. Additionally, 74% of patients are classified as functional Class III at baseline. Financially, the company reported $257.9 million in cash and equivalents, with a net loss of $36.6 million for the quarter. The discussion also covered the upcoming Phase III SERANATA study for pulmonary hypertension associated with interstitial lung disease (PH-ILD), which plans to enroll approximately 480 patients globally, aiming to demonstrate improvements in six-minute walk distance and forced vital capacity.Gossamer Bio Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
12
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 48.47M | 114.70M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 47.47M | 114.70M | 0.00 | 0.00 | 0.00 |
| EBITDA | -162.25M | -39.97M | -161.92M | -211.07M | -209.40M |
| Net Income | -170.37M | -56.53M | -179.82M | -229.38M | -234.00M |
Balance Sheet | |||||
| Total Assets | 172.25M | 315.29M | 311.92M | 272.45M | 343.66M |
| Cash, Cash Equivalents and Short-Term Investments | 136.93M | 294.52M | 296.43M | 255.68M | 325.22M |
| Total Debt | 201.97M | 202.88M | 212.46M | 225.74M | 185.24M |
| Total Liabilities | 295.01M | 285.80M | 249.15M | 260.37M | 222.19M |
| Stockholders Equity | -122.76M | 29.49M | 62.77M | 12.08M | 121.46M |
Cash Flow | |||||
| Free Cash Flow | -171.34M | -3.47M | -159.16M | -187.51M | -190.51M |
| Operating Cash Flow | -171.27M | -3.47M | -159.16M | -187.03M | -188.89M |
| Investing Cash Flow | 156.36M | 29.02M | -110.97M | -1.03M | -117.43M |
| Financing Cash Flow | 6.42M | -11.49M | 190.15M | 117.09M | 3.33M |
Gossamer Bio Technical Analysis
Neutral
0.40
Price Trends
0.99
Negative
2.02
Negative
2.13
Negative
Market Momentum
-0.15
Negative
35.99
Neutral
79.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GOSS, the sentiment is Neutral. The current price of 0.4 is above the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.99, and below the 200-day MA of 2.13, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 35.99 is Neutral, neither overbought nor oversold. The STOCH value of 79.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GOSS.
Gossamer Bio Risk Analysis
Gossamer Bio disclosed 79 risk factors in its most recent earnings report. Gossamer Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Gossamer Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.56B | -13.24 | -28.72% | ― | ― | -44.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $949.02M | -33.83 | -19.77% | ― | -10.26% | 144.62% | |
46 Neutral | $1.21B | -11.28 | -84.01% | ― | ― | -22.39% | |
41 Neutral | $94.02M | -3.72 | 264.70% | ― | -58.17% | -116.24% |
* Healthcare Sector Average
GOSS
Gossamer Bio
0.43
-0.40
-48.01%
CTMX
CytomX Therapeutics
4.54
3.91
619.49%
SVRA
Savara
6.07
3.14
107.17%
MBX
MBX Biosciences, Inc.
32.81
25.43
344.58%
Gossamer Bio Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Gossamer Bio Receives Nasdaq Minimum Bid Price Deficiency Notice
Negative
Apr 9, 2026
On April 8, 2026, Gossamer Bio disclosed that it received a Nasdaq notice stating its shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days from February 24 through April 7, 2026, though the notice does not...
Business Operations and StrategyProduct-Related Announcements
Gossamer Bio Reveals Mixed Phase 3 Seralutinib Results
Negative
Feb 23, 2026
On February 23, 2026, Gossamer Bio reported topline Phase 3 PROSERA data showing that seralutinib did not meet the prespecified statistical threshold on its primary endpoint of six‑minute walk distance at Week 24 in the overall pulmonary art...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.